Teniposide Injection

Product/Composition Teniposide Injection
Strength 50mg/5ml
Form Injection
Production Capacity 1 Million Injection/Month
Therapeutic use Anti Cancer
Package Insert/Leaflet Available upon request

Teniposide Injection

Category: Chemotherapy / Antineoplastic agent
Form: Injectable solution for intravenous (IV) use

Uses:

  • Treatment of hematologic malignancies, particularly childhood acute lymphoblastic leukemia (ALL).

  • Used in certain solid tumors, including neuroblastoma and brain tumors.

  • Often part of combination chemotherapy regimens.

Mechanism of Action:

  • Teniposide is a topoisomerase II inhibitor.

  • Interferes with the enzyme topoisomerase II, preventing DNA replication and repair in rapidly dividing cells.

  • Causes DNA strand breaks, leading to cell cycle arrest and apoptosis (cell death) in cancer cells.

Administration:

  • Administered intravenously over a period of time, often with prehydration and antiemetic therapy.

  • Dosage and schedule depend on type of cancer, patient weight, and overall health.

  • Usually given in cycles, with rest periods between doses to allow recovery of normal cells.

Side Effects:

  • Hematologic: leukopenia, thrombocytopenia, anemia (bone marrow suppression).

  • Gastrointestinal: nausea, vomiting, diarrhea, mucositis.

  • Neurological: peripheral neuropathy, dizziness.

  • Other: hair loss, allergic reactions at the injection site, fever.

  • Rare: secondary malignancies with long-term use.

Precautions:

  • Monitor complete blood count (CBC) regularly to avoid severe myelosuppression.

  • Use cautiously in patients with liver or kidney impairment.

  • Pre-medication with antiemetics may reduce nausea and vomiting.

  • Avoid extravasation during IV infusion to prevent tissue irritation or necrosis.

  • Dose adjustments may be necessary in elderly or frail patients.

Summary:
Teniposide Injection is a chemotherapy drug that inhibits topoisomerase II, leading to DNA damage and death of cancer cells. It is used primarily in childhood leukemias, certain solid tumors, and combination chemotherapy regimens. Administered intravenously, it requires careful monitoring of blood counts, liver and kidney function, and attention to side effects such as myelosuppression, nausea, and neuropathy.